[go: up one dir, main page]

MA51048B1 - Compositions comprenant des conjugues de polysaccharide-proteine de streptococcus pneumoniae et leurs procedes d'utilisation - Google Patents

Compositions comprenant des conjugues de polysaccharide-proteine de streptococcus pneumoniae et leurs procedes d'utilisation

Info

Publication number
MA51048B1
MA51048B1 MA51048A MA51048A MA51048B1 MA 51048 B1 MA51048 B1 MA 51048B1 MA 51048 A MA51048 A MA 51048A MA 51048 A MA51048 A MA 51048A MA 51048 B1 MA51048 B1 MA 51048B1
Authority
MA
Morocco
Prior art keywords
polysaccharide
pneumoniae
compositions
methods
protein
Prior art date
Application number
MA51048A
Other languages
English (en)
Other versions
MA51048A (fr
Inventor
William J. Smith
Patrick Mchugh
Michael Albert Winters
Julie M. Skinner
Jian He
Luwy MUSEY
Chitrananda Abeygunawardana
Yadong Adam CUI
Michael J. KOSINSKI
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MA51048A publication Critical patent/MA51048A/fr
Publication of MA51048B1 publication Critical patent/MA51048B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)

Abstract

L'invention concerne des compositions immunogènes multivalentes comprenant plus d'un conjugué polysaccharide-protéine de S. pneumoniae , chaque conjugué comprenant un polysaccharide provenant d'un sérotype de S. pneumoniae conjugué à une protéine porteuse, les sérotypes de S. pneumoniae étant tels que définis dans la description. Dans certains modes de réalisation, au moins l'un des conjugués polysaccharide-protéine est formé par une réaction de conjugaison comprenant un solvant aprotique. Dans d'autres modes de réalisation, chaque conjugué polysaccharide-protéine est formé par une réaction de conjugaison comprenant un solvant aprotique. L'invention concerne également des méthodes destinées à induire une réponse immunitaire protectrice chez un patient humain et consistant à administrer à ce patient des compositions immunogènes polyvalentes de l'invention. Ces compositions immunogènes polyvalentes sont utiles pour assurer une protection contre une infection à S. pneumoniae et des maladies provoquées par S. pneumoniae . Les compositions de l'invention sont également utiles en tant que partie de régimes de traitement qui fournissent une protection complémentaire aux patients qui ont été vaccinés avec un vaccin polyvalent indiqué pour la prévention d'une maladie pneumococcique.
MA51048A 2017-12-06 2018-12-04 Compositions comprenant des conjugues de polysaccharide-proteine de streptococcus pneumoniae et leurs procedes d'utilisation MA51048B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762595388P 2017-12-06 2017-12-06
EP18871825.8A EP3720483B1 (fr) 2017-12-06 2018-12-04 Compositions comprenant des conjugues de polysaccharide-proteine de streptococcus pneumoniae et leurs procedes d'utilisation
PCT/US2018/063709 WO2019139692A2 (fr) 2017-12-06 2018-12-04 Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation

Publications (2)

Publication Number Publication Date
MA51048A MA51048A (fr) 2021-03-17
MA51048B1 true MA51048B1 (fr) 2025-12-31

Family

ID=66334525

Family Applications (2)

Application Number Title Priority Date Filing Date
MA51048A MA51048B1 (fr) 2017-12-06 2018-12-04 Compositions comprenant des conjugues de polysaccharide-proteine de streptococcus pneumoniae et leurs procedes d'utilisation
MA051049A MA51049A (fr) 2017-12-06 2018-12-04 Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA051049A MA51049A (fr) 2017-12-06 2018-12-04 Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation

Country Status (28)

Country Link
US (5) US11116828B2 (fr)
EP (1) EP3720483B1 (fr)
JP (4) JP7369123B2 (fr)
KR (3) KR102573200B1 (fr)
CN (2) CN117982633A (fr)
AR (2) AR114154A1 (fr)
AU (2) AU2018400751B2 (fr)
BR (1) BR112020011414B8 (fr)
CL (1) CL2020001478A1 (fr)
CO (1) CO2020006882A2 (fr)
CR (2) CR20250169A (fr)
EA (1) EA202091382A1 (fr)
EC (1) ECSP20032085A (fr)
FI (1) FI3720483T3 (fr)
GE (2) GEP20227420B (fr)
IL (1) IL274954B (fr)
JO (1) JOP20200141A1 (fr)
MA (2) MA51048B1 (fr)
MX (2) MX2020005779A (fr)
NI (1) NI202000040A (fr)
NZ (1) NZ765694A (fr)
PE (1) PE20201338A1 (fr)
PH (1) PH12020550891A1 (fr)
PT (1) PT3720483T (fr)
SG (1) SG11202005255PA (fr)
TW (1) TWI725359B (fr)
UA (1) UA128603C2 (fr)
WO (1) WO2019139692A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016015835B1 (pt) * 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR102225282B1 (ko) * 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
ES3024474T3 (en) 2016-12-30 2025-06-04 Vaxcyte Inc Polypeptide-antigen conjugates with non-natural amino acids
KR20190108583A (ko) 2017-01-31 2019-09-24 머크 샤프 앤드 돔 코포레이션 다당류-단백질 접합체 제조 방법
EP3589314A4 (fr) 2017-02-24 2021-04-21 Merck Sharp & Dohme Corp. Amélioration de l'immunogénicité de conjugués de polysaccharide de streptococcus pneumoniae et de protéine
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
PL3678654T3 (pl) * 2017-09-07 2024-12-16 Merck Sharp & Dohme Llc Polisacharydy pneumokokowe i ich zastosowanie w immunogennych koniugatach polisacharyd-białko nośnikowe
CN117018172A (zh) 2017-09-07 2023-11-10 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
WO2019050814A1 (fr) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Polysaccharides antipneumococciques et leur utilisation dans des conjugués immunogènes polysaccharide-protéine porteuse
BR112020004471A8 (pt) 2017-09-07 2022-11-01 Merck Sharp & Dohme Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
EP3691677A4 (fr) 2017-10-04 2021-07-07 Pogona, Llc Compositions de conjugués saccharide-polypeptide et leurs procédés d'utilisation
US11116828B2 (en) * 2017-12-06 2021-09-14 Merck Sharp & Dohme Corp. Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
AU2019215216B2 (en) 2018-02-05 2025-04-17 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2019256218B2 (en) 2018-04-18 2025-10-16 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
CN120661645A (zh) 2018-04-30 2025-09-19 默沙东有限责任公司 生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
EP3787674A4 (fr) 2018-04-30 2022-01-26 Merck Sharp & Dohme Corp. Procédés de production de conjugués protéine porteuse-polysaccharide capsulaire de streptococcus pneumoniae à partir de lyosphères
WO2020121159A1 (fr) * 2018-12-12 2020-06-18 Pfizer Inc. Conjugués polysaccharide-protéine immunogènes à hétéroantigènes multiples et leurs utilisations
GEP20247633B (en) 2018-12-19 2024-06-25 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
MX2022001241A (es) 2019-07-31 2022-04-20 Sanofi Pasteur Inc Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
AU2021207701B2 (en) * 2020-01-17 2025-08-14 Bill & Melinda Gates Foundation Multivalent Streptococcus vaccines
WO2022035816A1 (fr) * 2020-08-10 2022-02-17 Inventprise, Llc Vaccins glycoconjugués pneumococciques multivalents contenant un sérotype 24f émergent
CA3200602A1 (fr) 2020-11-04 2022-05-12 Pfizer Inc. Compositions immunogenes destinees a etre utilisees dans des vaccins pneumococciques
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
EP4145124B1 (fr) * 2021-09-04 2025-09-10 Serum Institute of India Private Limited Procédé de surveillance de la stabilité de vaccins conjugués polysaccharide-protéine
CN120513083A (zh) 2022-12-01 2025-08-19 辉瑞大药厂 肺炎链球菌缀合物疫苗制剂
US20240390471A1 (en) 2023-05-18 2024-11-28 Merck Sharp & Dohme Llc Compounds and adjuvant formulations useful in pneumococcal vaccines
TW202532099A (zh) 2024-02-14 2025-08-16 美商默沙東有限責任公司 肺炎鏈球菌結合物疫苗及其使用方法

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
EP0027888B1 (fr) 1979-09-21 1986-04-16 Hitachi, Ltd. Interrupteur à semiconducteur
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2006700A1 (fr) 1989-01-17 1990-07-17 Antonello Pessi Peptides synthetiques et leur utilisation comme porteurs universels pour la preparation de conjugats immunogenes convenant a la mise au point de vaccins synthetiques
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
EP0482068A1 (fr) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine et supports d'hormone pour vaccins conjugues
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
CA2059692C (fr) 1991-01-28 2004-11-16 Peter J. Kniskern Vaccin conjugue de polysaccharide contre les pneumocoques
CA2059693C (fr) 1991-01-28 2003-08-19 Peter J. Kniskern Antigenes polysaccharides de streptococcus pneumoniae
ATE245446T1 (de) 1992-02-11 2003-08-15 Jackson H M Found Military Med Dualer träger für immunogene konstrukte
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2135052A1 (fr) 1992-05-06 1993-11-11 R. John Collier Region de la toxine diphterique qui est fixatrice du recepteur
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
PT616034E (pt) 1993-03-05 2005-02-28 Wyeth Corp Plasmideo para a producao de proteina crm e toxina da difteria
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE241384T1 (de) 1995-03-22 2003-06-15 Jackson H M Found Military Med Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
JPH10504842A (ja) 1995-06-06 1998-05-12 ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン 二重担体免疫原性構築物
US6420135B1 (en) 1996-10-31 2002-07-16 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
KR19980067137A (ko) 1997-01-31 1998-10-15 박원훈 알긴산염 초미세과립구를 이용한 폐렴구균 감연중에 대한 백신
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
DE122009000054I1 (de) 1999-03-19 2009-12-31 Glaxosmithkline Biolog Sa Impfstoff gegen bakterielle antigene
EP1165796A2 (fr) 1999-04-09 2002-01-02 Techlab, Inc. Support proteique recombinant de la toxine a pour vaccins conjugues polysaccharides
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
AU2001270381B2 (en) 2000-06-20 2007-05-24 Id Biomedical Corporation Streptococcus antigens
DZ3399A1 (fr) 2000-06-29 2002-01-03 Smithkline Beecham Biolog Composition de vaccin polyvalent
US7118756B2 (en) 2000-12-28 2006-10-10 Wyeth Recombinant protective protein from Streptococcus pneumoniae
CN1636062A (zh) 2001-04-16 2005-07-06 惠氏控股公司 编码多肽抗原的新肺炎链球菌可读框及其应用
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003009869A1 (fr) 2001-07-26 2003-02-06 Chiron Srl. Vaccins comprenant des adjuvants aluminium et histidine
GB0130215D0 (en) 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
EP1456231A2 (fr) 2001-12-20 2004-09-15 Shire Biochem Inc. Antigenes de streptococcus
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
WO2004071439A2 (fr) 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Preparation d'immunoglobuline et son procede de production
KR101052996B1 (ko) 2003-03-13 2011-07-29 글락소스미스클라인 바이오로지칼즈 에스.에이. 박테리아 세포용해소에 대한 정제 공정
CA2519511A1 (fr) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Holotoxine du cholera mutante en tant qu'adjuvant et proteine de support d'antigene
AU2003901717A0 (en) 2003-04-10 2003-05-01 Western Sydney Area Health Service Identification of streptococcus pneumoniae serotypes
DE102004017696A1 (de) * 2004-04-10 2005-10-27 Vorwerk & Co. Interholding Gmbh Bodenpflegegerät mit einer rotierbaren Bürste
EP1781326A4 (fr) 2004-06-04 2009-01-14 Pharmexa Inc Induction d'une reponse immunitaire contre des polysaccharides streptococcus pneumoniae
EP1828230A2 (fr) 2004-12-16 2007-09-05 Stichting Top Institute Food and Nutrition Nouvel efficient procédé de production de polysaccharides capsulaires de bactéries gram-positives pathogènes par expression hétérologue et sécrétion de polysaccharides complexes dans des bactéries gram-positives non-pathogènes et non-invasives
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN104815327A (zh) 2005-04-08 2015-08-05 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
HUE050049T2 (hu) 2005-04-08 2020-11-30 Wyeth Llc Szennyezõanyagok elválasztása streptococcus pneumoniae poliszacharidtól PH manipulációjával
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7764278B2 (en) 2005-06-30 2010-07-27 Seiko Epson Corporation Integrated circuit device and electronic instrument
PT1973564T (pt) 2005-12-22 2017-01-24 Glaxosmithkline Biologicals Sa Vacina compreendendo conjugados polissacarídicos capsulares de streptococcus pneumoniae
JP5285431B2 (ja) 2005-12-28 2013-09-11 ザ ユーエイビー リサーチ ファウンデイション 肺炎球菌血清型
CA2635208C (fr) 2005-12-28 2018-03-20 The Uab Research Foundation Streptococus pneumonia comportant une unite de repetition de polysaccharides capsulaires {>2)glucose 1(1>3) glucose 2 (1>3) rhamnose (1>3)ribitol (5>phosphate}
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
CA2660022C (fr) 2006-08-07 2014-11-04 President And Fellows Of Harvard College Vaccins a base de matrice proteique et procedes de fabrication et d'administration de tels vaccins
WO2008045852A2 (fr) 2006-10-10 2008-04-17 Wyeth Procédés améliorés pour la séparation de polysaccharides du type 3 de streptococcus pneumoniae
UA99278C2 (ru) 2007-03-23 2012-08-10 УАЙЕТ ЭлЭлСи Способ получения существенно очищенных капсульных полисахаридов из лизата клеток streptococcus pneumoniae
AU2008267208B2 (en) 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
US8540955B2 (en) 2007-07-10 2013-09-24 Wyeth Llc Process for producing aluminum phosphate
JP5789514B2 (ja) 2008-12-18 2015-10-07 ワイス・エルエルシー 二酸化炭素を用いて肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）多糖の分子量を制御するための方法
US8795689B2 (en) 2008-12-18 2014-08-05 Wyeth Llc Method for controlling Streptococcus pneumoniae serotype 19A polysaccharide molecular weight
CN101590224A (zh) 2009-06-30 2009-12-02 广州精达医学科技有限公司 高效14价肺炎球菌结合疫苗
CA2773690A1 (fr) 2009-09-09 2011-03-17 Matrivax Research & Development Corp. Vaccins a base d'une matrice proteique et a immunogenicite renforcee
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
DK2575870T3 (en) 2010-06-04 2017-02-13 Wyeth Llc vaccine Formulations
BR112013012626A2 (pt) 2010-12-10 2016-07-19 Merck Sharp & Dohme formulação, composição imunogênica, e, seringa pré-carregada
CN102068690A (zh) 2010-12-31 2011-05-25 北京民海生物科技有限公司 多价肺炎球菌荚膜多糖结合疫苗及其制备方法
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
BR112013029417B1 (pt) 2011-05-18 2022-10-25 Matrivax, Inc Composições de vacina de matriz proteica incluindo policátions e método de preparo das mesmas
BR112013032225A2 (pt) 2011-06-13 2016-08-16 Merck Sharp & Dohme método para purificar toxina de difteria, e, formulação
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CN103623401A (zh) 2012-08-23 2014-03-12 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法
CN103656632B (zh) 2012-09-24 2016-01-13 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖组合物、其制备方法及应用
CN103656631B (zh) 2012-09-24 2015-08-19 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白缀合物组合物及其制备方法
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
HUE060718T2 (hu) 2012-12-20 2023-04-28 Pfizer Glikokonjugációs eljárás
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
CN104069488A (zh) 2013-03-29 2014-10-01 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法
EP3607966A1 (fr) * 2014-01-21 2020-02-12 Pfizer Inc Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
BR112016015835B1 (pt) 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
HRP20211288T1 (hr) * 2014-01-21 2021-11-26 Pfizer Inc. Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati
FI3244917T3 (fi) 2015-01-15 2023-05-25 Pfizer Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi
KR102045663B1 (ko) 2015-05-04 2019-11-15 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
KR102876828B1 (ko) 2015-06-08 2025-10-27 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 다당류-단백질 접합체의 흡착을 개선시키는 방법 및 그로부터 수득된 다가 백신 제제
ES2857474T3 (es) 2015-06-23 2021-09-29 Biological E Ltd Vacuna conjugada neumocócica multivalente
WO2017011338A1 (fr) 2015-07-10 2017-01-19 President And Fellows Of Harvard College Couplage à médiation par la sortase de conjugués protéine-polysaccharide immunogène et leur utilisation
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
AU2016357567B2 (en) 2015-11-17 2020-05-07 Pfizer Inc. Media and fermentation methods for producing polysaccharides in bacterial cell culture
WO2017085586A1 (fr) 2015-11-20 2017-05-26 Pfizer Inc. Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
US11058757B2 (en) * 2016-03-31 2021-07-13 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
WO2017220753A1 (fr) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition de conjugué polysaccharide pneumococcique-protéine
CN105999254A (zh) 2016-06-27 2016-10-12 北京智飞绿竹生物制药有限公司 含2型和12f血清型的15价肺炎球菌结合物组合疫苗
WO2018009906A1 (fr) 2016-07-08 2018-01-11 President And Fellows Of Harvard College Conjugués cellules entières – protéines, et procédés de fabrication de ces derniers
CN109845298B (zh) 2016-07-27 2021-12-28 夏普株式会社 使用系统信息值标签的无线电信方法和装置
EP3493837B1 (fr) 2016-08-05 2022-08-31 Sanofi Pasteur, Inc. Composition de conjugué polysaccharide pneumococcique multivalent-protéine
CA3031797A1 (fr) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Composition d'un conjugue polysaccharide-proteine pneumococcique multivalent
MY192792A (en) 2016-09-06 2022-09-09 Lg Chemical Ltd A composition of multivalent pneumococcal capsular polysaccharide-carrier protein conjugates and use thereof
AU2017336806B2 (en) 2016-09-30 2024-06-27 Biological E Limited Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
KR20180043122A (ko) 2016-10-19 2018-04-27 동국대학교 산학협력단 신규링커를 통한 폐렴구균 다당류-단백질 접합체 백신 및 이의 용도
WO2018080213A1 (fr) 2016-10-28 2018-05-03 주식회사 엘지화학 Composition immunogène multivalente ayant un titre d'igg augmenté, et son utilisation
CN108144056A (zh) 2016-12-02 2018-06-12 武汉博沃生物科技有限公司 多价肺炎球菌多糖结合疫苗及其制备方法
SI3570879T1 (sl) 2017-01-20 2022-06-30 Pfizer Inc. Imunogenska kompozicija za uporabo v pnevmokoknih cepivih
KR102650073B1 (ko) 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
KR20190108583A (ko) 2017-01-31 2019-09-24 머크 샤프 앤드 돔 코포레이션 다당류-단백질 접합체 제조 방법
WO2018156465A1 (fr) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Conjugués polysaccharides-protéine utilisant le fragment b de la toxine diphtérique en tant que support
EP3589314A4 (fr) 2017-02-24 2021-04-21 Merck Sharp & Dohme Corp. Amélioration de l'immunogénicité de conjugués de polysaccharide de streptococcus pneumoniae et de protéine
WO2018156467A1 (fr) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Procédés d'amélioration de la filtrabilité de réactions de polysaccharide conjugué à une protéine
PT3585803T (pt) 2017-02-24 2025-12-22 Merck Sharp & Dohme Formulações de vacina pneumocócica conjugada
KR102101879B1 (ko) 2017-03-15 2020-05-29 주식회사 엘지화학 다가 폐렴구균 백신 조성물
CN107929728A (zh) 2017-04-19 2018-04-20 武汉博沃生物科技有限公司 一种肺炎球菌蛋白疫苗及其制备方法
EP3634481A4 (fr) 2017-06-10 2021-07-21 Inventprise, LLC. Vaccins conjugués multivalents avec des polysaccharides conjugués bivalents ou multivalents qui confèrent une immunogénicité et une avidité améliorées
CN109091668A (zh) 2017-06-20 2018-12-28 浙江博和瑞达生物科技有限公司 16价肺炎链球菌结合疫苗组合物
EP3668541A4 (fr) 2017-08-16 2021-05-26 Merck Sharp & Dohme Corp. Formulations de vaccin pneumococcique conjugué
JP2020533299A (ja) 2017-09-07 2020-11-19 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． キャリアタンパク質へのコンジュゲーションのための肺炎球菌多糖の製剤方法
BR112020004471A8 (pt) 2017-09-07 2022-11-01 Merck Sharp & Dohme Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
PL3678654T3 (pl) 2017-09-07 2024-12-16 Merck Sharp & Dohme Llc Polisacharydy pneumokokowe i ich zastosowanie w immunogennych koniugatach polisacharyd-białko nośnikowe
WO2019050814A1 (fr) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Polysaccharides antipneumococciques et leur utilisation dans des conjugués immunogènes polysaccharide-protéine porteuse
CN117018172A (zh) 2017-09-07 2023-11-10 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
EP3691677A4 (fr) 2017-10-04 2021-07-07 Pogona, Llc Compositions de conjugués saccharide-polypeptide et leurs procédés d'utilisation
JP2021501144A (ja) 2017-10-25 2021-01-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アジュバントワクチン
US11116828B2 (en) * 2017-12-06 2021-09-14 Merck Sharp & Dohme Corp. Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP2019118051A (ja) 2017-12-27 2019-07-18 株式会社デンソー 表示処理装置
CN108159408A (zh) 2017-12-29 2018-06-15 云南沃森生物技术股份有限公司 一种多价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用
CN108245674A (zh) 2018-01-18 2018-07-06 北京智飞绿竹生物制药有限公司 一种多价肺炎球菌结合物组合疫苗的处方及其制备方法
CN108079286B (zh) 2018-01-19 2020-07-31 云南沃森生物技术股份有限公司 一种13价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用
SG11202006387QA (en) 2018-02-05 2020-07-29 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2019215216B2 (en) 2018-02-05 2025-04-17 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2019170068A1 (fr) 2018-03-05 2019-09-12 武汉博沃生物科技有限公司 Vaccin contre le pneumocoque et procédé de préparation associé
AU2019256218B2 (en) 2018-04-18 2025-10-16 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
CN120661645A (zh) 2018-04-30 2025-09-19 默沙东有限责任公司 生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
EP3787674A4 (fr) 2018-04-30 2022-01-26 Merck Sharp & Dohme Corp. Procédés de production de conjugués protéine porteuse-polysaccharide capsulaire de streptococcus pneumoniae à partir de lyosphères
WO2019217183A1 (fr) 2018-05-07 2019-11-14 Merck Sharp & Dohme Corp. Sac de lyophilisation
CN108339115B (zh) 2018-05-11 2020-07-10 武汉博沃生物科技有限公司 使用重组载体蛋白的肺炎球菌联合疫苗及其制备方法
WO2019220304A1 (fr) 2018-05-14 2019-11-21 Tergene Biotech Pvt. Ltd. Vaccin conjugué de polysaccharide pneumococcique 15-valent
US20210223262A1 (en) 2018-06-07 2021-07-22 Merck Sharp & Dohme Corp. Lyosphere critical reagent kit
CN108524926B (zh) 2018-06-29 2021-06-29 康希诺生物股份公司 一种多价肺炎球菌结合疫苗的制剂组合及其应用
WO2020009462A1 (fr) 2018-07-06 2020-01-09 주식회사 유바이오로직스 Composition immunogène multivalente comprenant des conjugués polysaccharide-protéine et vaccin la comprenant pour prévenir une maladie provoquée par streptococcus pneumoniae
CN108543066A (zh) 2018-07-17 2018-09-18 成都安特金生物技术有限公司 一种24价肺炎球菌多糖疫苗及其鉴别方法
BR112021001144A2 (pt) 2018-07-21 2021-04-20 Biological E Limited formulações da vacina compreendendo sistema conservante
EP3852795A4 (fr) 2018-09-23 2022-11-23 Biological E Limited Polysaccharides capsulaires purifiés de streptococcus pneumoniae
JP7558944B2 (ja) 2018-10-12 2024-10-01 バイオロジカル イー リミテッド 多価肺炎球菌多糖類－タンパク質コンジュゲートワクチン
CN109336989B (zh) 2018-10-22 2022-05-13 北京智飞绿竹生物制药有限公司 一种通过粘度控制制备肺炎球菌荚膜多糖的方法
WO2020121159A1 (fr) 2018-12-12 2020-06-18 Pfizer Inc. Conjugués polysaccharide-protéine immunogènes à hétéroantigènes multiples et leurs utilisations
GEP20247633B (en) 2018-12-19 2024-06-25 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2020152706A1 (fr) 2019-01-21 2020-07-30 Biological E Limited Compositions de vaccins pneumococciques conjugués polyvalents
WO2020157772A1 (fr) 2019-01-28 2020-08-06 Biological E Limited Compositions vaccinales à base de conjugués polysaccharide-protéine pneumococcique multivalentes
CN109771640A (zh) 2019-02-28 2019-05-21 北京智飞绿竹生物制药有限公司 多价肺炎球菌结合疫苗
CA3136278A1 (fr) 2019-04-10 2020-10-15 Pfizer Inc. Compositions immunogenes comprenant des antigenes saccharidiques capsulaires conjugues, kits les comprenant et leurs utilisations
WO2020247299A1 (fr) 2019-06-05 2020-12-10 Merck Sharp & Dohme Corp. Conjugué polysaccharide pneumococcique de sérotype 35b immunogène et de protéine, et procédé de conjugaison pour la fabrication de celui-ci
MX2021014948A (es) 2019-06-05 2022-01-24 Merck Sharp & Dohme Llc Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae.
CN110302375A (zh) 2019-06-27 2019-10-08 康希诺生物股份公司 一种糖缀合物及其用途
CN110365663A (zh) 2019-06-28 2019-10-22 北京淇瑀信息科技有限公司 一种隔离集群之间的访问方法、装置及电子设备
PH12022550133A1 (en) 2019-07-18 2022-11-14 Celltrion Inc Immunogenic composition comprising multivalent streptococcus pneumoniae polysaccharide-protein conjugates and pharmaceutical use thereof
MX2022001241A (es) 2019-07-31 2022-04-20 Sanofi Pasteur Inc Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
CN111821432B (zh) 2020-08-05 2022-10-18 北京智飞绿竹生物制药有限公司 一种多价肺炎球菌结合疫苗

Also Published As

Publication number Publication date
AU2018400751A1 (en) 2020-06-18
KR20230006024A (ko) 2023-01-10
JP7458682B2 (ja) 2024-04-01
CO2020006882A2 (es) 2020-06-19
CA3084436A1 (fr) 2019-07-18
BR112020011414B1 (pt) 2022-09-27
JP2024023417A (ja) 2024-02-21
JOP20200141A1 (ar) 2022-10-30
MX2024006606A (es) 2024-06-12
FI3720483T3 (fi) 2026-01-12
NI202000040A (es) 2020-09-24
JP2021505589A (ja) 2021-02-18
PH12020550891A1 (en) 2021-04-12
BR112020011414B8 (pt) 2023-01-31
TWI725359B (zh) 2021-04-21
ECSP20032085A (es) 2020-08-31
EP3720483A2 (fr) 2020-10-14
US11850278B2 (en) 2023-12-26
NZ765694A (en) 2024-03-22
AU2018400751B2 (en) 2022-07-21
US12097250B2 (en) 2024-09-24
KR20230130153A (ko) 2023-09-11
MA51049A (fr) 2020-10-14
WO2019139692A2 (fr) 2019-07-18
MX2020005779A (es) 2020-10-28
WO2019139692A3 (fr) 2019-08-15
KR102686858B1 (ko) 2024-07-19
EA202091382A1 (ru) 2021-01-15
AR114154A1 (es) 2020-07-29
SG11202005255PA (en) 2020-07-29
US11116828B2 (en) 2021-09-14
KR102481327B1 (ko) 2022-12-23
MA51048A (fr) 2021-03-17
CR20250169A (es) 2025-05-26
CN117982633A (zh) 2024-05-07
BR122021023687A2 (fr) 2020-12-01
PE20201338A1 (es) 2020-11-25
GEAP202215382A (en) 2022-06-10
IL274954B (en) 2021-10-31
US20210177957A1 (en) 2021-06-17
BR122021023687A8 (pt) 2023-02-07
IL274954A (en) 2020-07-30
GEP20227420B (en) 2022-10-10
JP7369123B2 (ja) 2023-10-25
AU2022209360B2 (en) 2024-11-14
UA128603C2 (uk) 2024-08-28
JP2025024036A (ja) 2025-02-19
KR20200096266A (ko) 2020-08-11
US20210379174A1 (en) 2021-12-09
EP3720483B1 (fr) 2025-11-19
US20240108711A1 (en) 2024-04-04
AR126443A2 (es) 2023-10-11
CR20200245A (es) 2020-07-17
CN111683678A (zh) 2020-09-18
US20190192648A1 (en) 2019-06-27
JP2022130553A (ja) 2022-09-06
CL2020001478A1 (es) 2020-12-18
CN111683678B (zh) 2024-01-26
KR102573200B1 (ko) 2023-08-31
TW201925458A (zh) 2019-07-01
JP7587666B2 (ja) 2024-11-20
BR112020011414A2 (pt) 2020-12-01
US20240398925A1 (en) 2024-12-05
AU2022209360A1 (en) 2022-09-29
PT3720483T (pt) 2026-01-12

Similar Documents

Publication Publication Date Title
MA51048B1 (fr) Compositions comprenant des conjugues de polysaccharide-proteine de streptococcus pneumoniae et leurs procedes d'utilisation
PH12021551448A1 (en) Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
Glueck Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization
CO6270339A2 (es) Formulaciones de vacuna meningococica
BR112021024491A2 (pt) Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição
HU229968B1 (hu) Sztreptokokkusz oltóanyag
BR9910749A (pt) Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma
EA200601761A1 (ru) Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения
DK1740217T3 (da) Meningokok-konjugat-vaccination
MX2020003756A (es) Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
MX2015013401A (es) Procedimiento de tratamiento.
EA202191647A1 (ru) Композиции, содержащие конъюгаты полисахарида из streptococcus pneumoniae и белка, и способы их применения
ECSP22031077A (es) Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación
MX2023005221A (es) Composiciones inmunogenicas para uso en vacunas neumococicas.
ZA202402956B (en) Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
Manis et al. New conjugated pneumococcal vaccine. Does it decrease the incidence of acute otitis media?